Potassium Channel Activator Attenuates Salicylate-Induced Cochlear Hearing Loss Potentially Ameliorating Tinnitus by Wei Sun et al.
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ORIGINAL RESEARCH ARTICLE
published: 07 April 2015
doi: 10.3389/fneur.2015.00077
Potassium channel activator attenuates salicylate-induced
cochlear hearing loss potentially ameliorating tinnitus
Wei Sun1*, Jun Liu2, Chao Zhang2, Na Zhou3, Senthilvelan Manohar 1,WendyWinchester 4,
Jason A. Miranda4 and Richard J. Salvi 1
1 Center for Hearing and Deafness, State University of New York at Buffalo, Buffalo, NY, USA
2 Department of Otolaryngology, General Hospital of PLA, Beijing, China
3 Department of Otolaryngology, Peking University Third Hospital, Beijing, China
4 Neusentis Research Unit, Pfizer, Cambridge, UK
Edited by:
Jinsheng Zhang, Wayne State
University, USA
Reviewed by:
Huiming Zhang, University of
Windsor, Canada
Jian Wang, Dalhousie University,
Canada
*Correspondence:
Wei Sun, Center for Hearing and
Deafness, State University of New
York at Buffalo, 137 Cary Hall, Buffalo,
NY 14214, USA
e-mail: weisun@buffalo.edu
High dose sodium salicylate causes moderate, reversible hearing loss and tinnitus.
Salicylate-induced hearing loss is believed to arise from a reduction in the electromotile
response of outer hair cells (OHCs) and/or reduction of KCNQ4 potassium currents in
OHCs, which decreases the driving force for the transduction current. Therefore, enhanc-
ing OHC potassium currents could potentially prevent salicylate-induced temporary hearing
loss. In this study, we tested whether opening voltage-gated potassium channels using
ICA-105665, a novel small molecule that opens KCNQ2/3 and KCNQ3/5 channels, can
reduce salicylate-induced hearing loss. We found that systemic application of ICA-105665
at 10 mg/kg prevented the salicylate-induced amplitude reduction and threshold shift in the
compound action potentials recorded at the round window of the cochlea. ICA-105665
also prevented the salicylate-induced reduction of distortion-product otoacoustic emis-
sion. These results suggest that ICA-105665 partially compensates for salicylate-induced
cochlear hearing loss by enhancing KCNQ2/3 and KCNQ3/5 potassium currents and the
motility of OHCs.
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INTRODUCTION
Aspirin, with sodium salicylate as an active ingredient, is one of
the most widely used analgesic, anti-inflammatory, and antipyretic
drugs (1). Sodium salicylate at a high dose (1–10 mM) can induce
a moderate, reversible cochlear hearing loss (~20–40 dB thresh-
old elevation), tinnitus, and suppression of otoacoustic emissions
(OAEs) (2, 3). These perceptual changes have generally been
attributed to functional impairments in the cochlea such as a
down regulation of the electromotile response of outer hair cells
(OHCs) and a decrease in neural output of the cochlea (4–9). The
effect of salicylate on OHC electromotility at a high concentra-
tion (>1 mM) is likely due to its competition for the chloride
anion binding site on the prestin motor protein, rather than
plasma membrane mechanics (7). A more recent study found that
at moderate concentrations (0.1–1 mM), salicylate also causes a
concentration-dependent reversible reduction of a voltage-gated
potassium channel, which is encoded by KCNQ4 gene of OHCs
(10). This subsequently may depolarize the OHC, which would
reduce the net driving force of the transduction current thereby
diminishing OHC electromotility. Thus, there are at least two
mechanisms by which salicylate can cause an OHC-based cochlear
hearing loss.
KCNQ genes encode a family of five voltage-gated potassium
channels, i.e., KCNQ1 through KCNQ5, and KCNQ channel has
six transmembrane domains and a single pore loop (11). In the
cochlea, all members of the KCNQ family have been identified
(11, 12). KCNQ4 channels are expressed on hair cells and spiral
ganglion neurons (13, 14) and the mutation of KCNQ4 accounts
for human non-syndromic deafness DFNA2 an autosomal dom-
inant hearing loss (15). Since the resting potential of OHC is
dependent on potassium currents, KCNQ4 mutation can reduce
IK, which leads to selective degeneration of OHCs (16). In addi-
tion, KCNQ2 is expressed in the modiolus and organ of corti,
synaptic regions under hair cells, spiral ganglion auditory neurons,
and nerve fibers innervating hair cells (12). KCNQ3 was detected
in the cochlear lateral wall. Although the immunocytochemistry
study did not clearly identify KCNQ2/3 on OHCs, M-like cur-
rents, which are mediated by KCNQ2/3 and KCNQ3/5 channels
(17–20), have been recorded in isolated guinea pig OHCs (21).
M-currents are low-threshold depolarization-activated potassium
currents that can be inhibited by the cholinergic agonist muscarine
(22). M-currents play a role in stabilizing the resting membrane
potential, which is important for regulating cellular excitability
and K+ homeostasis (23). However, the function of KCNQ2/3
and KCNQ3/5 in salicylate-induced cochlear hearing loss is poorly
understood. The recently identified KCNQ5 channels, often co-
expressed with KCNQ3 channels, are expressed in the synaptic
endings in the auditory brainstem and the calyx terminals of type
I vestibular hair cells (24). Therefore, we tested the effects of ICA-
105665, a novel small molecule that selectively opens KCNQ2/3
and KCNQ3/5 channels (Kv7.2/7.3 and Kv7.3/7.5) (25, 26) to
determine its effects on salicylate-induced hearing loss.
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EXPERIMENTAL PROCEDURES
ANIMALS
Twenty-one adult male Sprague-Dawley rats (3–5 months, 200–
400 g) were used for the physiological recordings. All protocols
were approved by the Institutional Animal Care and Use Com-
mittee (IACUC) of the State University of New York at Buffalo
that conform to the guidelines issued by the National Institutes of
Health. This research minimized the number of animals used and
their suffering.
SURGERY
Rats were anesthetized with a mixture of ketamine (50 mg/kg)
and xylazine (6 mg/kg). The bulla of the left ear was exposed
and a silver ball electrode was placed on the round window (27).
Body temperature was measured and maintained using a heat-
ing pad (Homeothermic blanket control unit, Harvard Apparatus,
MA, USA). Compound action potentials (CAPs) were recorded
before and after the delivery of sodium salicylate (250 mg/kg,
i.p.) with/without ICA-105665 (10 mg/kg, i.m.). Since the peak
concentration of ICA-105665 occurred ~1 h after the injection
(manuscript in preparation), ICA-105665 was always injected 1 h
before salicylate treatment. Sodium salicylate (S-2679, Sigma, St.
Louis, MO, USA) was dissolved in Ringer’s solution (25 mg/ml).
ICA-105665 (100 mg) was first dissolved in 50µl of DMSO and
950µl of methylcellulose, and then dissolved in 19 ml of water
to make a final ICA-105665 concentration of 5 mg/ml. This dose
resulted in a mean ICA-105665 unbound plasma concentration
of 69.1 nM± 9.5 SEM, which is a pharmacologically relevant level
for selectivity of this compound. The ICA-105665 in vitro EC50
(concentration at which 50% of the maximum effect is achieved)
for cloned rat KCNQ2/3 channels is 160 nM with high selectivity
at this exposure level (25) (manuscript in preparation).
ACOUSTICAL STIMULI AND RECORDINGS
Stimuli were generated with hardware from Tucker-Davis Tech-
nologies (TDT, Alachua, FL, USA) and software (SigGen, TDT)
and presented through a high frequency speaker (Fostex FT28D,
Fostex, Tokyo, Japan). Tone-bursts (2 ms duration and 1 ms
rise/fall) at 4, 8, 12, 16, and 32 kHz were used to elicit the CAP
at intensities ranging from 25 to 95 dB SPL (10 dB step). Stimuli
were calibrated using a sound level meter (824, Larson Davis,
Depew, NY, USA) with a half inch microphone (Larson Davis,
model #2559).
The output of the silver ball electrode used to record the CAP
was connected to a preamplifier (RA16LA, TDT) using a flexible,
low noise cable. The output of the preamplifier was delivered to
a digital signal processing module (RX5-2, Pentusa Base Station,
TDT) connected to a computer. The electrical response was dig-
itized (25 kHz), filtered (100–3000 Hz), and averaged (n= 1024)
over a 10 ms sampling window.
DPOAE RECORDINGS
The distortion-product otoacoustic emissions (DPOAE) were
recorded in a separate group of rats (n= 8) using a Smart DPOAE
system (Intelligent Hearing Systems, FL, USA). A pair of continu-
ous tones (F1 and F2) was used to elicit the DPOAE. The F2 testing
frequencies were from 4 to 24 kHz and the ratio of F2 to F1 was set
at 1.2. The F2 testing intensities ranged from 15 to 60 dB with 5 dB
step (the intensity of F1 was 10 dB higher than F2). In four rats,
the DPOAEs were recorded prior to and 1 h after salicylate treat-
ment. In the other four rats, the baseline DPOAEs was recorded
and then the rats were treated with ICA-105665 (10 mg/kg, i.m.).
One hour after ICA-105665 treatment, DPOAEs were recorded
and then the rats were treated with salicylate (250 mg/kg, i.p.) and
DPOAEs were recorded 1 h afterward.
STATISTIC DATA ANALYSIS
The graphs and statistical analyses were performed using Graph-
Pad Prism version 5.00 for Windows (GraphPad Software, San
Diego, CA, USA) unless otherwise noted. Results are presented as
mean± SEM.
RESULTS
ICA-105665 ATTENUATED SALICYLATE’S EFFECT ON COCHLEA
The threshold and the amplitude of CAPs recorded from the round
window of anesthetized rats were monitored before, and at 1 and
2 h after treatment with salicylate (250 mg/kg, i.p.) with/without
ICA-105665 (10 mg/kg, i.p.). Salicylate treatment caused a large
reduction of the CAP amplitude and noticeable threshold shifts.
Figure 1A shows typical CAP waveforms recorded before and after
FIGURE 1 | Effects of ICA-105665 on compound action potential (CAP)
threshold shifts induced by salicylate (SS). (A)Typical CAP response
recorded from the round window of cochlea elicited by a tone-burst stimulus
(8 kHz, 80 dB SPL). (B,C) Significant threshold shifts of CAP were induced by
high doses of SS (250 mg/kg, i.p.). ICA-105665 (10 mg/kg, i.p., n=7)
treatment caused a significant reduction of CAP threshold shifts at 8, and
32 kHz on 1 h, and 8, 16, and 32 kHz on 2 h after salicylate injection (Student’s
t -test, df=11, P values were listed inTable 1).
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salicylate treatment. Figures 1B,C show the threshold shifts of the
CAP at 1 and 2 h after salicylate injection. The CAP threshold
significantly increased 1–2 h after salicylate injection. The aver-
age CAP threshold shifts were 18± 4.7, 19± 2.7, 25± 4.4, and
40± 6.8 dB (n= 6) at 4, 8, 16, and 32 kHz 1 h after salicylate
injection and slightly less at 2 h. To determine if ICA-105665
could prevent salicylate-induced hearing loss, a separate group
of rats were treated with ICA-105665 (10 mg/kg, i.p., n= 7) 1 h
before 250 mg/kg salicylate administration. One hour after ICA-
105665 was injected, the CAP threshold showed no obvious shift
(the average CAP shift was 0.8± 0.8, 6.6± 4.9, 6.6± 3.3, and
2.8± 3.2 dB at 4, 8, 16, and 32 kHz, respectively, n= 6). The
CAP threshold and amplitude were measured 1–2 h after salicy-
late injection. The CAP threshold shifts were 14± 1.7, 6.4± 1.5,
17± 1.7, and 15± 3.6 dB at 4, 8, 16, and 32 kHz 1 h after ICA-
105666 plus salicylate treatment. There was a significant difference
between the salicylate treated group and the ICA-105665 plus
salicylate treated group at 8 and 32 kHz on 1 h and 8, 16, and
32 kHz on 2 h after salicylate injection (Student’s t -test, df= 11,
P values were listed in Table 1). There was no significant dif-
ference at 4 kHz on 1 and 2 h, and 16 kHz on 1 h treatment
(Table 1).
Table 1 | Student’s t -test on CAP threshold shifts caused by salicylate
(250mg/kg, i.p.) vs. salicylate plus ICA-105665 (df=11).
4 kHz 8kHz 16kHz 32kHz
1 h treatment P =0.14 P =0.001** P =0.06 P =0.006**
2 h treatment P =0.11 P =0.007** P =0.017* P =0.001**
*P<0.05, **P<0.01.
The CAP amplitudes were measured in both groups before
and after salicylate injection (Figures 2A–H). The CAP amplitude
dropped significantly at 4, 8, 16, and 32 kHz after salicylate
injection with/without ICA-105665 application (10 mg/kg). The
average amplitude decrease caused by salicylate with/without ICA-
105665 was evaluated at 95 dB SPL. Salicylate caused a mean
(±SEM,N = 5) decrease of 34± 6, 61± 7, 58± 10, and 33± 23%
at 4, 8, 16, and 32 kHz 2 h after salicylate treatment (n= 5). In the
ICA-105665 plus salicylate group, the CAP mean (±SEM, n= 5)
amplitude decrease at 95 dB SPL was 27± 7, 25± 9, 34± 13, and
36± 16% decrease 2 h after salicylate treatment (n= 6). Figure 3
shows the mean reduction of CAP amplitude at 95 dB SPL-induced
salicylate with/without ICA-105665 treatment. There was no sig-
nificant difference between the CAP amplitude reduction in the
salicylate alone group with the salicylate plus ICA-105665 group at
1 h post-treatment (Student’s t -test,P > 0.05), but there was a sig-
nificant difference at 8 kHz for the 2 h treatment groups (Student’s
t -test, P = 0.017, t = 2.9, df= 9).
DISTORTION-PRODUCT OTOACOUSTIC EMISSION
The effects of salicylate, ICA-105665 and ICA-105665 plus sal-
icylate on DPOAE (4–24 kHz), are shown in Figures 4 and 5.
Salicylate induced a decrease in DPOAE amplitude at all tested fre-
quencies and more changes were found in the high frequencies. To
determine if the ICA-105665 could prevent the salicylate-induced
DPOAE decrease, rats were treated with ICA-105665 (10 mg/kg,
i.p., n= 4) and then with salicylate 1 h later. After ICA-105665
plus salicylate treatment, the DPOAE amplitudes were signifi-
cantly larger than those in the salicylate alone group at 16 and
24 kHz (40–60 dB SPL). Since the increase in DPOAE ampli-
tude with ICA-105665 plus salicylate vs. salicylate alone mainly
occurred at higher intensities, we did linear regression analysis
FIGURE 2 |The input–output functions of CAP before and after salicylate treatment with/without ICA-105665. (A–D)The CAP amplitude change induced
by salicylate treatment (250 mg/kg, i.p.) at 4, 8, 16, and 32 kHz. (E–H)The CAP amplitude change caused by salicylate and ICA-105665 (10 mg/kg, i.p., n= 7) at 4,
8, 16, and 32 kHz.
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FIGURE 3 |The reduction of CAP amplitude at 95dB SPL induced by
salicylate with/without ICA-105665 treatment. There was no significant
difference between the CAP amplitude reduction in the salicylate alone
group with the salicylate plus ICA-105665 group at 1 h post-treatment (A,
Student’s t -test, P >0.05), but there was a significant difference at 8 kHz
for the 2 h treatment groups (B, Student’s t -test, t =2.9, df=9).
FIGURE 4 |The effects of salicylate and ICA-105665 on the amplitudes
of distortion-product otoacoustic emissions (DPOAE). (A–F) Salicylate
induced a significant decrease in DPOAE amplitude at all frequencies
(4–24 kHz, two-way ANOVA, P <0.001). Treatment with ICA-105665 prior to
salicylate injection lessened the SS-induced DPOAE reductions at high
frequencies. The slopes of the DPOAE amplitude–intensity functions before
and after the treatment of salicylate with/without ICA-105665 were
significant at 13, 16, and 24 kHz, but not on 4, 6, and 8 kHz (the F and P
values were listed inTable 2).
FIGURE 5 | ICA-105665 treatment showed a slight increase on DPOAE
amplitudes at high frequencies (D–F), not at low frequencies (A–C).
However, the difference was not significant due to the small sample size.
on the DPOAE amplitude–intensity function at 40–60 dB SPL
for each animal on each frequency. The slopes of the DPOAE
amplitude–intensity functions were used for statistical analysis.
We found that the slope of the DPOAE amplitude–intensity func-
tion (40–60 dB SPL) before and after the treatment of salicylate
with/without ICA-105665 were significantly different at 13, 16,
and 24 kHz, but not on 4, 6, and 8 kHz (the F and P values
were listed in Table 2). Figure 5 showed that after ICA-105665
treatment, the DPOAE amplitude showed a slight increase. How-
ever, post Tukey’s tests showed a significant difference at 13, 16,
and 24 kHz between before and after SS with/without ICA-105665
treatment. This difference was likely caused by the effect of ICA-
105665, which enhanced the amplitude of DPOAE. There was no
significant difference between before and after ICA-105665 treat-
ment. This may be due to the small sample size has been tested in
the experiment.
DISCUSSION
Salicylate-induced sensorineural hearing loss is mainly caused by
down regulation of the electromotile response of OHCs, which
decreases the neural output of cochlea (4–9). In our experi-
ment, we found that the activation of cochlear potassium chan-
nels using ICA-105665, an activator of KCNQ2/3 and KCNQ3/5
channels, can decrease salicylate-induced CAP amplitude reduc-
tion and threshold shifts. Since ICA-105665 also caused an
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Table 2 | One-way ANOVA test on the slopes of DPOAE amplitude–intensity function (40–60dB SPL) before and after the treatment of salicylate
(SS) with/without ICA-105665.
Pre SS SS+ ICA ICA df F P
4 kHz 0.44±0.20 0.56±0.12 0.38±0.08 0.82±0.19 3,15 2.58 0.12
6 kHz 0.35±0.27 0.47±0.12 0.62±0.20 0.28±0.12 3,15 0.89 0.47
8 kHz 0.46±0.50 0.55±0.17 0.55±0.17 −0.2±0.05 3,15 1.49 0.28
13 kHz 0.42±0.25 0.90±0.10 0.77±0.13 −0.07±0.15 3,15 5.81 0.01*
16 kHz 0.86±0.05 1.44±0.21 1.58±0.12 0.84±0.09 3,15 10.58 0.002**
24 kHz 0.88±0.19 1.41±0.12 1.55±0.18 0.56±0.07 3,15 8.04 0.006**
*P<0.05, **P<0.01.
increase of DPOAE amplitude, our study suggests that ICA-105665
can compensate for salicylate-induced hearing loss presumably
by enhancing the electromotility of OHC through activating
potassium currents.
KCNQ2, KCNQ3, and KCNQ5 are co-expressed in many
regions of the cochlea (11, 28), including OHCs, spiral ganglion
neurons, and the lateral wall of the cochlea (12, 15). KCNQ2/3 and
KCNQ3/5 are heteromeric channels that may underlie M-currents,
which are important in maintaining neuronal excitability (17). M-
like currents have been recorded in isolated OHCs in the guinea
pig cochlea (21). These currents can be activated at more depo-
larized potentials than other voltage-gated K+ channels and may
be involved in maintaining auditory excitability. We found that
activation of KCNQ2/3 and KCNQ3/5 enhanced DPOAE ampli-
tude; these results suggest that activation of M-channel-mediated
potassium currents may be involved in electromotility of OHCs.
The enhancements of DPOAE amplitude by ICA-105665 were sig-
nificant at high, but not low frequencies. This suggests that more
KCNQ channels are expressed in the basal than the apical turn of
cochlea. The expression of KCNQ4 in the IHCs and spiral ganglion
neurons decreased from the base to the apex of the cochlea (13).
However, there is no report on the gradient of KCNQ2, KCNQ3, or
KCNQ5 expression in the cochlea. Since ICA-105665 can activate
both KCNQ2/3 and KCNQ3/5 channels, it is unclear whether one
channel or the other is responsible for effects on CAP and DPOAE
or whether a combined effect is driving these differences.
KCNQ2/3 and KCNQ5 are also broadly expressed in the brain,
including hippocampus, caude-putamen, globus pallidus, cor-
tex, thalamus, hypothalamus, and midbrain cortex (18, 29–31).
Reduction of KCNQ-mediated currents can increase neuronal
excitability to epileptogenic levels and cause convulsion (32).
KCNQ2/3 openers, such as ICA-27243, can shift the activation
of KCNQ2/3 to a hyperpolarized potential and prevent epilepsy
(33). ICA-105665, a new generation of anti-seizure drug target-
ing KCNQ2/3 channels, was tested for efficacy in several epilepsy
models because of its selectivity for potassium channels (25, 26).
Unlike other anti-seizure drugs such as retigabine, which also
potentiate GABAa receptor response at slightly higher concen-
trations, ICA-105665 is more selective and does not affect GABAa
receptor responses (33). A recent clinical study reported that ICA-
105665 at single doses of 100–500 mg reduced photoparoxysmal
responses elicited by 2–60 Hz light flash in patients with epilepsy
(34). In our preliminary studies, we also found that ICA-105665
can directly affect the firing properties of neurons in the auditory
cortex and the inferior colliculus. However, ICA-105665 failed to
reduce salicylate-induced hyperexcitability in the auditory cortex,
which suggests that ICA-105665 and salicylate may target differ-
ent receptors and channels in the central auditory system (data
not included).
In summary, ICA-105665, an activator of KCNQ2/3 and
KCNQ3/5 channels, reduced the toxic effects of salicylate on
the amplitude of the CAP and DPOAE. Since ICA-105665 alone
enhanced the amplitude of DPOAEs, we speculate that the drug
exerts its protective effects against salicylate ototoxicity by target-
ing the KCNQ2/3 and or KCNQ3/5 channels. ICA-105665 may
be a useful compound in protecting against ototoxicity and noise
exposure by enhancing the OHC motility.
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